Irvine-based TAE Life Sciences, which is developing technology originally used at nuclear reactors to develop a next-generation method to treat cancers, appointed Rob Hill as its new chief executive officer.
Hill replaced Bruce Bauer who had served as CEO since the company was founded in 2017 and is stepping aside for medical reasons. He will remain active on the board of directors as chairman emeritus.
Hill joined TAE Life Sciences as chief operating officer in 2018.
“I’m confident that our Alphabeam BNCT machine, combined with our proprietary targeted drugs, will profoundly impact the lives of patients worldwide,” Hill said in a statement. “With our exceptional team, we’ll bring this groundbreaking therapy to market, and make a meaningful difference in the fight against cancer.”
